These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 16161389)

  • 1. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence.
    Kenton K; Lowenstein L; Brubaker L
    Neurourol Urodyn; 2010 Apr; 29(4):555-7. PubMed ID: 19771598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine.
    Nurs Times; 2006 Jun 6-12; 102(23):27. PubMed ID: 16784047
    [No Abstract]   [Full Text] [Related]  

  • 14. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Overactive bladder. New anticholinergic drug controls urinary urge].
    MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
    [No Abstract]   [Full Text] [Related]  

  • 16. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.